briciclib
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2009 (NCT01049113)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- G1/S-specific cyclin D1INHIBITOR
CCND1 inhibitor
Prodrug of ON-013100
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(OP(=O)(O)O)c2)c(OC)c1- Mol. weight
- 474.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1206245 ↗
- ChEMBLCHEMBL3137303 ↗
Also known as
- briciclib
- briciclib
- briciclib
- briciclib
- briciclib sodium
- briciclib sodium
- on 013105
- on 013105
- on 013105
- on-013105
- on-013105
- on 014185
- on 014185
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02168725 | Phase 1 | Jun 1, 2014 | Onconova Therapeutics, Inc., University of Colorado, Denver |
| NCT01049113 | Phase 1 | Nov 1, 2009 | Onconova Therapeutics, Inc., University of South Florida |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Onconova Therapeutics, Inc. | For profit | 2 | 2 | 1 | 2009 |
| University of Colorado, Denver | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of South Florida | Academic/Hospital | 1 | 0 | 1 | 2009 |
3 organizations
Page 1 / 1